JP2022519595A5 - - Google Patents
Info
- Publication number
- JP2022519595A5 JP2022519595A5 JP2021545400A JP2021545400A JP2022519595A5 JP 2022519595 A5 JP2022519595 A5 JP 2022519595A5 JP 2021545400 A JP2021545400 A JP 2021545400A JP 2021545400 A JP2021545400 A JP 2021545400A JP 2022519595 A5 JP2022519595 A5 JP 2022519595A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098698A JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800999P | 2019-02-04 | 2019-02-04 | |
| US62/800,999 | 2019-02-04 | ||
| US201962818677P | 2019-03-14 | 2019-03-14 | |
| US62/818,677 | 2019-03-14 | ||
| PCT/US2020/016623 WO2020163365A2 (en) | 2019-02-04 | 2020-02-04 | Combination gene targets for improved immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Division JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519595A JP2022519595A (ja) | 2022-03-24 |
| JPWO2020163365A5 JPWO2020163365A5 (https=) | 2023-02-10 |
| JP2022519595A5 true JP2022519595A5 (https=) | 2023-02-10 |
Family
ID=71947815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545400A Pending JP2022519595A (ja) | 2019-02-04 | 2020-02-04 | 免疫療法の改善のための遺伝子標的の組み合わせ |
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200347386A1 (https=) |
| EP (1) | EP3920942A4 (https=) |
| JP (2) | JP2022519595A (https=) |
| KR (1) | KR20210138587A (https=) |
| CN (1) | CN113396216A (https=) |
| AU (1) | AU2020217715A1 (https=) |
| BR (1) | BR112021015170A2 (https=) |
| CA (1) | CA3128823A1 (https=) |
| IL (1) | IL285307A (https=) |
| MX (1) | MX2021009357A (https=) |
| SG (1) | SG11202108452WA (https=) |
| WO (1) | WO2020163365A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11261428B2 (en) | 2018-03-15 | 2022-03-01 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| TW202227625A (zh) * | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除 |
| WO2022133329A1 (en) * | 2020-12-17 | 2022-06-23 | University Of Florida Research Foundation, Incorporated | Method for programmable control of rna transcript levels with autoregulated crispr-cas13d |
| EP4288541A1 (en) | 2021-02-05 | 2023-12-13 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| EP4305153A1 (en) | 2021-03-09 | 2024-01-17 | CRISPR Therapeutics AG | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
| WO2023015213A1 (en) * | 2021-08-03 | 2023-02-09 | Spotlight Therapeutics | Ptpn2 specific guide rnas and uses thereof |
| AU2022366987A1 (en) | 2021-10-14 | 2024-05-16 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| WO2023082640A1 (zh) * | 2021-11-10 | 2023-05-19 | 清华大学 | 增强免疫细胞持久性的方法 |
| MX2024006243A (es) * | 2021-11-23 | 2024-06-11 | Kumquat Biosciences Inc | Compuestos que contienen heteroatomos y usos de estos. |
| JP2025501358A (ja) * | 2022-01-05 | 2025-01-17 | 蘇州系統医学研究所 | Ｔ細胞受容体、その製造方法、及び使用 |
| EP4471128A4 (en) * | 2022-01-29 | 2026-03-04 | Suzhou Grit Biotechnology Co Ltd | Modified tumor infiltrating lymphocyte and use thereof |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| CN116790667A (zh) * | 2023-07-12 | 2023-09-22 | 中国医科大学 | 巨噬细胞条件性基因敲除小鼠模型的建立及其应用 |
| WO2025054946A1 (zh) * | 2023-09-15 | 2025-03-20 | 毕诺济(上海)生物技术有限公司 | 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用 |
| WO2025082418A1 (zh) * | 2023-10-18 | 2025-04-24 | 苏州沙砾生物科技有限公司 | 一种鉴定靶标的方法及其应用 |
| CN117883382B (zh) * | 2023-11-27 | 2025-02-14 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途 |
| WO2025126049A2 (en) * | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2025223340A1 (zh) * | 2024-04-22 | 2025-10-30 | 苏州沙砾生物科技有限公司 | 一种鉴定靶标的方法及其应用 |
| WO2026064475A1 (en) * | 2024-09-18 | 2026-03-26 | Editas Medicine, Inc. | Crispr cas-related methods and compositions targeting ptpn2 expression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
| JP2008522951A (ja) * | 2004-07-19 | 2008-07-03 | ベイラー・カレツジ・オブ・メデイシン | サイトカインシグナル伝達調節物質の調節および免疫療法のための応用 |
| US20130331294A1 (en) * | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
| WO2010098429A1 (ja) * | 2009-02-27 | 2010-09-02 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| ES2897579T3 (es) * | 2013-06-10 | 2022-03-01 | Dana Farber Cancer Inst Inc | Métodos y composiciones para reducir la inmunosupresión por células tumorales |
| AU2014346559B2 (en) * | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
| WO2015188228A1 (en) * | 2014-06-10 | 2015-12-17 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| WO2018148378A1 (en) * | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy |
| EP3765608A4 (en) * | 2018-03-15 | 2022-01-12 | KSQ Therapeutics, Inc. | GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY |
| CN116322716A (zh) * | 2020-09-23 | 2023-06-23 | 克里斯珀医疗股份公司 | Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性 |
-
2020
- 2020-02-04 MX MX2021009357A patent/MX2021009357A/es unknown
- 2020-02-04 CA CA3128823A patent/CA3128823A1/en active Pending
- 2020-02-04 WO PCT/US2020/016623 patent/WO2020163365A2/en not_active Ceased
- 2020-02-04 CN CN202080012560.2A patent/CN113396216A/zh active Pending
- 2020-02-04 BR BR112021015170-2A patent/BR112021015170A2/pt unknown
- 2020-02-04 JP JP2021545400A patent/JP2022519595A/ja active Pending
- 2020-02-04 SG SG11202108452WA patent/SG11202108452WA/en unknown
- 2020-02-04 US US16/781,732 patent/US20200347386A1/en active Pending
- 2020-02-04 KR KR1020217028228A patent/KR20210138587A/ko not_active Ceased
- 2020-02-04 AU AU2020217715A patent/AU2020217715A1/en active Pending
- 2020-02-04 EP EP20751889.5A patent/EP3920942A4/en active Pending
-
2021
- 2021-08-02 IL IL285307A patent/IL285307A/en unknown
-
2024
- 2024-06-19 JP JP2024098698A patent/JP2024111155A/ja active Pending